Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul-Aug;6(4):1145-51.
doi: 10.1021/mp900036s.

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys

Lucie Durand-Gasselin  1 , Koen K A Van Rompay, Jennifer E Vela, Ilana N Henne, William A Lee, Gerry R Rhodes, Adrian S Ray
Affiliations

Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys

Lucie Durand-Gasselin et al. Mol Pharm. 2009 Jul-Aug.

Abstract

The antiviral drug tenofovir (TFV) is orally administered as the fumarate salt of its disoproxil prodrug (TFV disoproxil fumarate (TDF)). TFV is a dianion at physiological pH and, as a result, has poor lipid membrane permeability. Administration of the lipophilic and cell-permeable prodrug, TFV disoproxil, enhances the oral absorption of TFV. In order to determine whether oral administration of TDF also increases distribution to sites of viral infection, the plasma and circulating lymphoid cell pharmacokinetics of TFV and its phosphorylated metabolites were assessed following a single oral TDF or subcutaneous TFV administration at doses yielding equivalent plasma exposures to TFV in macaques. Despite TFV disoproxil's lack of plasma stability and undetectable levels in the first plasma samples taken, oral administration of TDF resulted in 7.9-fold higher peripheral blood mononuclear cell exposures to the active metabolite, TFV-diphosphate. The apparent plasma terminal half-life (t(1/2)) of TFV was also longer following oral TDF relative to subcutaneous TFV administration (median t(1/2) of 15.3 and 3.9 h, respectively), suggesting broader distribution to cells and tissues outside of the central plasma compartment. In conclusion, the disoproxil pro-moiety enhances not only the oral absorption of TFV but also tissue and lymphoid cell loading. These results illustrate that administration of even a fleeting prodrug can increase target tissue loading and give valuable insight for future prodrug development.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of TFV and the fumarate salt of its orally bioavailable disoproxil prodrug (TDF).
Figure 2
Figure 2
Pharmacokinetic profiles of TFV in plasma following a single administration of either 4 mg/kg subcutaneous TFV (filled circles) or 30 mg/kg oral TDF (open circles) to macaques. Values represent the median (minimum-maximum) of 5 monkeys dosed with each regimen in a sequential study design with a 6 week washout period.
Figure 3
Figure 3
Pharmacokinetic profiles of TFV (A), TFV-MP (B) and TFV-DP (C) in PBMC following a single administration of either 4 mg/kg subcutaneous TFV (filled circles) or 30 mg/kg oral TDF (open circles) to macaques. Values represent the median (minimum-maximum) of 5 monkeys dosed with each regimen in a sequential study design with a 6 week washout period.
Figure 4
Figure 4
Intracellular levels of the endogenous nucleotides dATP (A) and dGTP (B) in PBMC following administration of either 4 mg/kg subcutaneous TFV (filled circles) or 30 mg/kg oral TDF (open circles) to macaques. Values represent the median (minimum-maximum) of 5 monkeys dosed once with each regimen in a sequential study design with a 6 week washout period.
See this image and copyright information in PMC

References

    1. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 1998;42:612–617. - PMC - PubMed
    1. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 2001;45:2733–2739. - PMC - PubMed
    1. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 2004;43:595–612. - PubMed
    1. Lee WA, He GX, Eisenberg E, Cihlar T, Swaminathan S, Mulato A, Cundy KC. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 2005;49:1898–1906. - PMC - PubMed
    1. van Gelder J, Deferme S, Naesens L, De Clercq E, van den Mooter G, Kinget R, Augustijns P. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 2002;30:924–930. - PubMed

Publication types